Summary of Clinical Use

Fezakinumab (ILV-094) has reached Phase 2 for atopic dermatitis (NCT01941537 ongoing), rheumatoid arthritis (NCT00883896 completed) and Phase 1 for psoriasis (NCT00563524 completed).

Mechanism Of Action and Pharmacodynamic Effects

IL-22, an IL-10 superfamily cytokine, plays a key role during inflammatory responses. Blocking or neutralising anti-IL-22 antibodies inhibit IL-22 activity, thereby reducing inflammation. Fezakinumab binds IL-22, effectively preventing formation of the IL-22/IL-22 receptor complex and inhibiting downstream signalling.